Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Artelo Biosciences Logo
Artelo Biosciences Growth Score
91
CB Rank
49721
Heat Score
68
Artelo Biosciences aims to accelerate the development and commercialization of endocannabinoid system modulating therapeutics.
Founded
obfuscation
PublicPost-IPO Equity La Jolla, California, United States1-10 artelobio.com
Biotechnology
Life Science
Pharmaceutical
Overview

Artelo Biosciences
Total Funding
obfuscation
Growth Score
91
Heat Score
68

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score91
-4 pts
in past quarter
Heat Score 68
-18 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Artelo Biosciences

CB Rank
49721
Artelo Biosciences aims to accelerate the development and commercialization of endocannabinoid system modulating therapeutics.
Founded
obfuscation
PublicPost-IPO Equity La Jolla, California, United States1-10 artelobio.com
Biotechnology
Life Science
Pharmaceutical

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name Artelo Biosciences, Inc.
Operating Status Active
Stock Symbol  NASDAQ:ARTL
Company Type For Profit
About the Company

Artelo Biosciences is a biopharmaceutical company dedicated to applying true biopharma discipline in leveraging past research and leading-edge, world-class science to accelerate the development and commercialization of a diverse portfolio of novel, endocannabinoid system modulating therapeutics. Its programmes have the potential to dramatically

improve patient care in major markets.

Phone Number +1 760 943 1689
Contact Email info@artelobio.com
Predictions & Insights

Growth Insight

See this Growth Insight
Artelo Biosciences is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

ART26.12
A selective inhibitor of Fatty Acid Binding Protein 5 (FABP5) designed to modulate lipid-signaling pathways for treating conditions like chemotherapy-induced peripheral neuropathy and certain cancers.
ART27.13
An orally administered dual CB1 and CB2 cannabinoid receptor agonist developed to address cancer anorexia and cachexia by increasing appetite and reducing muscle wasting.

Research & Development

Artelo Biosciences is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 8
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Artelo Biosciences Logo
Post-IPO Equity - Artelo Biosciences
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Artelo Biosciences Logo
Post-IPO Equity - Artelo Biosciences
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Artelo Biosciences Logo
Post-IPO Equity - Artelo Biosciences
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Artelo Biosciences Logo
Post-IPO Equity - Artelo Biosciences
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Artelo Biosciences Logo
Post-IPO Equity - Artelo Biosciences
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 8
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Artelo Biosciences Logo
Post-IPO Equity - Artelo Biosciences
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Artelo Biosciences Logo
Post-IPO Equity - Artelo Biosciences
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Artelo Biosciences Logo
Post-IPO Equity - Artelo Biosciences
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Artelo Biosciences Logo
Post-IPO Equity - Artelo Biosciences
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Artelo Biosciences Logo
Post-IPO Equity - Artelo Biosciences
—
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Photo of Bartosz Lipiński
Bartosz Lipiński
Yes
Post-IPO Equity - Artelo Biosciences Logo
Post-IPO Equity - Artelo Biosciences
—
Photo of Bartosz Lipiński
Bartosz Lipiński
Yes
Post-IPO Equity - Artelo Biosciences Logo
Post-IPO Equity - Artelo Biosciences
—
Photo of Bartosz Lipiński
Bartosz Lipiński
Yes
Post-IPO Equity - Artelo Biosciences Logo
Post-IPO Equity - Artelo Biosciences
—
Photo of Bartosz Lipiński
Bartosz Lipiński
Yes
Post-IPO Equity - Artelo Biosciences Logo
Post-IPO Equity - Artelo Biosciences
—
Photo of Bartosz Lipiński
Bartosz Lipiński
Yes
Post-IPO Equity - Artelo Biosciences Logo
Post-IPO Equity - Artelo Biosciences
—
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 5 Board Members and Advisors 2 Contacts 6

Employee Profiles

Board Members and Advisors

News

News and Press

News•May 27, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 26, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 26, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 26, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

1,449
-60.29%
 in past month

IT Spend

$789.1KThis year, Artelo Biosciences is projected to spend $789.1K on IT, according to Aberdeen.

Active Website Tech Count

6Artelo Biosciences is actively using 6 technologies for its website, according to BuiltWith. These include Apache, CommonCrawl Top 5m, and  Pound Sterling.
Sub-Organizations
Frequently Asked Questions

Where is Artelo Biosciences's headquarters? Artelo Biosciences is located in La Jolla, California, United States.Who invested in Artelo Biosciences? Artelo Biosciences is funded by Bartosz Lipiński.When was the last funding round for Artelo Biosciences? Artelo Biosciences closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Artelo Biosciences's competitors? Alternatives and possible competitors to Artelo Biosciences may include Sagimet Biosciences, KeifeRx, and  Dr. May Organics.How much funding has Artelo Biosciences raised to date? Artelo Biosciences has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(8fe006b 1)
|